Navigation Links
Biopure Granted Additional 180 Day Compliance Period by NASDAQ
Date:6/12/2008

CAMBRIDGE, Mass., June 12 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that The NASDAQ Stock Market has granted the Company an additional 180 days, or until December 8, 2008, to regain compliance with Marketplace Rule 4310(c)(4) requiring a minimum bid price of $1.00 for continued listing. Currently, the Company meets all other required inclusion criteria for the NASDAQ Capital Market. If, at any time before December 8, 2008, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will be provided written notification that it complies with the Marketplace Rule.

If compliance with the Marketplace Rule cannot be demonstrated by December 8, 2008, NASDAQ will issue a delisting notice to the Company.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The company is developing Hemopure for other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since its launch.

Tiana Gorham

Biopure Corporation

(617) 234-6826

IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biopure Announces MHRA Meeting Update
2. Biopure Announces 2008 Second Quarter Financial Results
3. Biopure Appoints Dechra Exclusive U.S. Distributor of Oxyglobin
4. Biopure Announces Date to Meet with UKs Medicines and Healthcare Products Agency
5. Biopure Operations Compliant With U.K. Manufacturing Guidelines
6. Biopure Appoints New Independent Auditor
7. Biopure Completes U.K. Regulatory Agency Inspection
8. Biopure Announces 2008 First Quarter Financial Results
9. Biopure Launches Updated Website
10. Biopure Announces Pricing of Equity Offering
11. Biopure Gives Update on Malaysia Joint Venture Discussions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):